Preterm birth prevention by 17 alpha-hydroxyprogesterone caproate vs. daily nursing surveillance

Journal of Reproductive Medicine for the Obstetrician and Gynecologist

Volumn 54, Issue 2, 2009, Pages 47-52

  Rittenberg, Charles ^a,b   Newman, Roger B ^a,b   Istwan, Niki B ^a,b   Rhea, Debbie J ^a,b   Stanziano, Gary J ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b Matria Healthcare Inc   (United States)

Author keywords

17 Alpha hydroxyprogesterone; Home uterine activity monitoring; Perinatal nursing surveillance; Preterm birth prevention

Indexed keywords

HYDROXYPROGESTERONE CAPROATE; UTERUS SPASMOLYTIC AGENT;

ADULT; ARTICLE; COMPARATIVE STUDY; FEMALE; HOME MONITORING; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; NURSING CARE; PATIENT MONITORING; PREMATURE LABOR; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; UTERUS CONTRACTION;

ADULT; FEMALE; GESTONORONE CAPROATE; HOME CARE SERVICES; HUMANS; INJECTIONS, INTRAMUSCULAR; MONITORING, AMBULATORY; OBSTETRIC LABOR, PREMATURE; PREGNANCY; PREMATURE BIRTH; PROGESTINS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 62849111161     PISSN: 00247758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Newman RB: Uterine contraction assessment. Obstet Gynecol Clin North Am 2005;32:341-367
2. Morrison JC, Martin JN, Martin RW, et al: Prevention of preterm birth by ambulatory assessment of uterine activity: A randomized study. Am J Obstet Gynecol 1987;156:536-543
3. Meis PJ, Klevanoff M, Thorn E, et al: Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 2003;348:2379-2385
4. Sexton DJ, O'Reilley MW, Friel AM, et al: Functional effects of 17alpha-hydroxyprogesterone caproate (ITP) on human myometrial contractility in vitro. Reprod Biol Endocrinol 2004;2:80-85
5. Ruddock N, Shi S, Jain S, et al: Progesterone (P4) but not 17alpha hydroxyprogesterone caproate (ITP) inhibits human myometrial contractions. Am J Obstet Gynecol 2007;197:S6
6. Mesiano S: Myometrial progesterone responsiveness and the control of human parturition. J Soc Gynecol Invest 2004;11:193-202
7. da Fonseca EB, Bittar RE, Carvalho MH, et al: Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: A randomized placebo-controlled double blind study. Am J Obstet Gynecol 2003;1884:419-424
8. Facchinetti F, Paganelli S, Comitini G, et al: Cervical length changes during preterm cervical ripening: Effects of 17 alpha hydroxyprogesterone caproate. Am J Obstet Gynecol 2007; 196:453.e1-453.e4
9. Pieber D, Allport VC, Hills F, et al: Interactions between progesterone receptor isoforms in myometrial cells in human labour. Mol Hum Reprod 2001;7:875-879
10. Sanchez-Ramos L, Kaunitz AM, Delke I: Progestational agents to prevent preterm birth: A meta-analysis of randomized controlled trials. Obstet Gynecol 2005;105:273-279
11. American College of Obstetricians and Gynecologists: ACOG Committee Opinion No 291: Use of progesterone to reduce preterm birth. Obstet Gynecol 2003;102:1115-1116
12. Ness A, Dias T, Damus K, et al: Impact of recent randomized trials on the use of progesterone to prevent preterm birth: A 2005 follow-up survey. Am J Obstet Gynecol 2006;195:1174-1179
13. Gonzalez-Quintero VH, Istwan NB, Rhea DJ, et al: Gestational age at initiation of 17-hydroxyprogesterone caproate (17P) and recurrent preterm delivery. J Matern Fetal Neonatal Med 2007;20:249-252
14. How H, Barton J, Istwan N, et al: Prophylaxis with 17 alpha-hydroxyprogesterone for prevention of recurrent preterm delivery: Does gestational age at initiation of treatment matter? Am J Obstet Gynecol 2007;197:260e1-4
15. Merkatz RB, Merkatz IR: The contributions of the nurse and the machine in home uterine activity monitoring systems. Am J Obstet Gynecol 1991;164:1159-1162
16. Iams JD, Johnson FF, O'Shaughnessy RW: A prospective randomized trial of home uterine activity monitoring in pregnancies at increased risk of preterm labor: Part II. Am J Obstet Gynecol 1988;159:595-603
17. Dyson DC, Daube KH, Bamber JA, et al: Monitoring women at risk for preterm labor. N Engl J Med 1998;338:15-19
18. Hill WC, Fleming AD, Martin RW, et al: Home uterine activity monitoring is associated with a reduction in preterm birth. Obstet Gynecol 1990;76:13-18
19. Dyson DC, Crites YM, Ray DA: Prevention of preterm birth in high risk patients: The role of education and provider contact versus home uterine activity monitoring. Am J Obstet Gynecol 1991;164:756-762
20. Committee on Obstetric Practice: ACOG Committee Opinion No 172: Home Uterine Activity Monitoring. Washington, American College of Obstetricians and Gynecologists, 1992
21. US Preventive Services Task Force: Home uterine activity monitoring for preterm labor: Review article. J Am Med Assoc 1993;270:371-376
22. Katz M, Newman RB, Gill PJ: Assessment of uterine activity in ambulatory patients at high risk of preterm labor and delivery. Am J Obstet Gynecol 1986;156:44-47
23. Nageotte MP, Dorchester W, Porto M, et al: Quantitation of uterine activity preceding preterm, term and post term labor. Am J Obstet Gynecol 1988;158:1254-1259
24. Mou SM, Sunderji SG, Gall S, et al: Multicenter randomized clinical trial of home uterine activity monitoring for detection of preterm labor. Am J Obstet Gynecol 1991;165:858-866
25. Corwin MJ, Mou SM, Sunderji SG, et al: Multicenter randomized clinical trial of home uterine activity monitoring: Pregnancy outcomes for all women randomized. Am J Obstet Gynecol 1996;175:1281-1285
26. Wapner RJ, Cotton DB, Artal R, et al: A randomized multicenter trial assessing a home uterine activity monitoring device used in the absence of daily nursing contact. Am J Obstet Gynecol 1995;172:1026-1035
27. Berkman MD, Thorp JM, Lohr KN, et al: Tocolytic treatment for the management of preterm labor: A review of the evidence. Am J Obstet Gynecol 2003;188:1648-1659